inMIND: Positive phase 3 results for tafasitamab combination in FL

The combination of tafasitamab, lenalidomide, and rituximab yielded clinically relevant benefits in survival outcomes in patients with relapsed or refractory follicular lymphoma (FL). Together with an acceptable safety profile, this regimen may potentially represent a new standard-of-care option for this indication. The phase 3 inMIND study (NCT04680052) randomised 548 participants with FL 1:1 to the CD19-targeting monoclonal antibody tafasitamab plus lenalidomide and rituximab, or to placebo plus lenalidomide and rituximab [1]. The included patients had received at least 1 prior systemic therapy, including an anti-CD20 monoclonal antibody. The primary endpoint was progression-free survival (PFS), and Prof. Marek Trneny (Charles University, Czech Republic) presented the results. After a median follow-up of 14.1 months, the median PFS was 22.4 months in the taf...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 18 June 20252 September 2025